en · de · es · fr · pt
sermorelin-notes.peptides9002.com › Guide › Melanocortin Receptor Pharmacology — 2026 Update

Melanocortin Receptor Pharmacology — 2026 Update

By Editorial Desk · published 2026-05-27 · last reviewed 2026-06-27 · Guide

The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-06-27 and is reviewed periodically as new material appears.

Melanocortin Receptor Pharmacology

Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.

The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.

Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.

Analytical Characterisation and Storage Practice

The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.

Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.

Pt-141 at a glance

PropertyValueNotes
Primary receptor targetMC4RHighest reported agonist potency within the family
Secondary receptor activityMC1R and MC3RLower potency than at MC4R
Elimination half-lifeAbout 2 to 3 hoursMeasured after subcutaneous administration
Plasma protein bindingApproximately 44 percentSpecies- and assay-dependent
Route of administrationSubcutaneous injectionReviewed product uses a single-use device

Bremelanotide Background and Receptor Pharmacology

PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.

Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.

Related pages on this site

Development History And Regulatory Status

PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.

Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.

Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.

Background from the literature

BASF announced that the transaction would allow the company to focus on its chemical and refinery catalysts business. Since 2016, BASF has partnered with a subsidiary of Xinjiang Zhongtai Group, a company sanctioned under the Uyghur Forced Labor Prevention Act, to operate a plant in Korla. In October 2017, BASF announced it would buy seed and herbicide businesses from Bayer for €5.9 billion ($7 billion), as part of Bayer's acquisition of Monsanto. The company announced the start of a US$10 billion investment project in the south-western Chinese city of Zhanjiang, in November 2019. The project was approved in 2022. This ″Verbund″ site is intended for the production of engineering plastics and TPU. The site would be the third-largest BASF site worldwide, following Ludwigshafen, Germany, and Antwerp, Belgium. The first plant started up in 2022, and the entire site is expected to be completed by 2030.

== External links == Transporter Classification Database List at qmul.ac.uk Saier MH, Tran CV, Barabote RD (January 2006). "TCDB: the Transporter Classification Database for membrane transport protein analyses and information". Nucleic Acids Res. 34 (Database issue): D181–6. doi:10.1093/nar/gkj001. PMC 1334385. PMID 16381841. Busch W, Saier MH (2002). "The transporter classification (TC) system, 2002". Crit. Rev. Biochem. Mol. Biol. 37 (5): 287–337. doi:10.1080/10409230290771528. PMID 12449427. S2CID 10558982. Classification of human transporters in pharmacology

On 28 June 1914, Franz Joseph's nephew and heir presumptive Archduke Franz Ferdinand, and his morganatic wife Sophie, Duchess of Hohenberg, were assassinated by Gavrilo Princip, a Yugoslav nationalist of Serbian ethnicity, during a visit to Sarajevo. Franz Joseph learned about the assassination of Franz Ferdinand from his adjutant, cavalry General Eduard von Paar, who also wrote the emperor's reaction in his diary: "one has not to defy the Almighty. In this manner a superior power has restored that order which I unfortunately was unable to maintain." While the emperor was shaken, and interrupted his holiday to return to Vienna, he soon resumed his vacation at his Kaiservilla at Bad Ischl. Initial decision-making during the "July Crisis" fell to Count Leopold Berchtold, the Imperial foreign minister; Count Franz Conrad von Hötzendorf, the chief of the Austro-Hungarian General Staff and the other ministers. The ultimate resolution of deliberations by the Austro-Hungarian government during the weeks following the assassination of the Archduke was to give Serbia an ultimatum of itemized demands that would reveal the conspirators in assassination of the archduke. However Serbia, despite no involvement in the plot, attempted to cover up the conspirators by either saying one of the conspirators never existed or being vague with the details. For Austria-Hungary, it was a matter of security as the Black hand had been terrorising Bosnia for years and had even attempted to assassinate the governor of Bosnia in 1910.

=== Obesity and insulin resistance === Much of what is hypothesized about a resistin role in energy metabolism and T2DM can be derived from studies showing strong correlations between resistin and obesity, the premise being that serum resistin levels increase with increased adiposity. Conversely, serum resistin levels decline with decreased adiposity following medical treatment. Specifically, central obesity (waistline adipose tissue) is the region of adipose tissue that contributes most to rising levels of serum resistin. This is significant, considering the link between central obesity and insulin resistance, two marked peculiarities of T2DM. On the other hand, at least one study has found no correlation between resistin levels and obesity or insulin resistance in humans, so the resistin–insulin resistance connection may be regarded as somewhat unsettled. Although resistin levels increase with obesity, it is questioned whether this increase is responsible for the insulin resistance associated with increased adiposity. Several reports have shown a positive correlation between resistin levels and insulin resistance. This is supported by reports of correlation between resistin levels and subjects with T2DM. If resistin contributes to the pathogenesis of insulin resistance in T2DM, then designing drugs to promote decreased serum resistin in T2DM subjects may deliver therapeutic benefits.

Sources: en.wikipedia.org

Further detail

=== Controversies === In 2018 UA received funding from the Pioneer Fund, a non-profit institute which promotes scientific racism and eugenics. The funds were applied for by Aurelio Jose Figueredo, who directs the graduate program on human behavior and evolutionary psychology. Funds from the grant were used by Figueredo to attend the 2016 London Conference on Intelligence, where presentations on eugenics are given. Figueredo has also reviewed papers for Mankind Quarterly, a journal which has advocated for racial hierarchy. Figueredo has disavowed eugenics and racial inferiority.

The cost of data loggers has been declining over the years as technology improves and costs are reduced. Simple single-channel data loggers can cost as little as $25, while more complicated loggers may cost hundreds or thousands of dollars.

=== Tempe semangit === In Indonesia, ripe tempeh (two or more days old) is considered a delicacy. Names include tempe semangit ('stinky tempeh') in Java, hampir busuk ('almost rotten') tempeh or tempe kemarin ('yesterday tempeh'). Having a slightly pungent aroma, small amounts are used as a flavoring agent in traditional Javanese sayur lodeh vegetable stew and sambal tumpang.

Sources: en.wikipedia.org

Frequently asked questions

Which receptors does bremelanotide activate?

Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.

Does the compound reach the brain?

Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.

What is known about its half-life?

Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.

Why is reversed-phase HPLC the default method?

The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.

Network